Rite Aid vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
US pharmacy chain that emerged from Chapter 11 bankruptcy (filed October 2023) following $1.3B+ opioid settlements; competing with CVS and Walgreens with a restructured reduced store network.
About
Rite Aid is a US pharmacy retail chain — historically one of the three largest US drugstore networks alongside CVS and Walgreens — operating neighborhood pharmacies providing prescription medications, immunizations, health screenings, and personal care retail. Founded in 1962 in Scranton, Pennsylvania and headquartered in Camp Hill, Pennsylvania, Rite Aid filed for Chapter 11 bankruptcy protection in October 2023 under the combined pressure of opioid litigation settlements exceeding $1.3 billion, real estate liabilities from 2,200+ store leases, declining pharmacy reimbursement rates from PBMs, and debt from the 2007 acquisition of Eckerd pharmacies. Rite Aid emerged from bankruptcy in 2024 with a restructured balance sheet and reduced store network, closing hundreds of locations while maintaining operations in core markets.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.